Biocompatibility and Effectiveness Evaluation of a New Hemostatic Embolization Agent: Thrombin Loaded Alginate Calcium Microsphere

Table 1

Banff 97 inflammation score and giant cell score of TACMs.

	72 h follow-up (range)	4 w follow-up (range)	12 w follow-up (range)
Banff 97 score	0.70 ± 0.46 (0-1)	0.34 ± 0.47 (0-1)	0.28 ± 0.45 (0-1)
Giant cell score	0.08 ± 0.27 (0-1)	0.30 ± 0.46 (0-1)	0.38 ± 0.49 (0-1)

Banff 97 score: 0 = no arteritis; 1 = mild-to-moderate intimal arteritis; 2 = severe intimal arteritis with at least 25% luminal area lost; 3 = transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate in vessel. Giant cell score: 0 = absence of giant cells; 1 = giant cells surround less than one-third of the particle circumference; 2 = giant cells surround >1/3 to <2/3 of the particle circumference; 3 = giant cells surround >2/3 of the particle circumference. The following comparisons were statistically significant: Banff 97 score: 72 h group versus 4 w group (); 72 h group versus 12 w group (); giant cell score: 72 h group versus 4 w group (); 72 h group versus 12 w group (). Data were presented as mean ± SD; ranges are in brackets [25].